MedTrace Logo

Virtual Reality and D-Cycloserine in Combat Related Psycological Trauma in Burn Service Members

NCT00855153 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2011-12-20

No results posted yet for this study

Summary

The purpose of this pilot study is to begin the examination of the feasibility of using Gradual Virtual Reality Exposure Therapy and D-Cycloserine (DCS) in the management of posttraumatic psychological symptoms in burned OIF/OEF military combatants.

The purpose of a feasibility study is to determine if there is clinical utility in this proposed treatment and to establish effective and safe treatment procedures. Given current literature, the following hypotheses are generated:

Hypothesis 1: Virtual Reality Exposure and D-Cycloserine medication (VRE + DCS learning pill) will result in clinically meaningful PTSD symptom reduction.

1. SMs will attain scores that are lower than initial measures for symptoms of PTSD
2. By the completion of VRE, Ss will attain scores in the sub-clinical range for measures of clinical depression Hypothesis 2: SMs will report greater life satisfaction following completion of VR+DCS treatment, as measured by scores on the Quality of Life Inventory (QOLI) when compared to pre-treatment scores

Conditions

  • Psychological Trauma

Interventions

OTHER

VR (Virtual reality)

VR stimulation of combat scenarios utilized as the exposure therapy tool.

DRUG

D-Cycloserine

50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment

Sponsors & Collaborators

  • United States Army Institute of Surgical Research

    lead FED

Principal Investigators

  • Kathryn M Gaylord, RN, PhD · US Army Institute of Surgical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00855153 on ClinicalTrials.gov